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Abstract 
The Gla-domain of human factor IX contains a specific element required for the binding of factor IX to an endothelial cell surface protein. We 
have investigated the dependence of this interaction on the structural integrity of the adjacent hydrophobic stack and epidermal growth factor-like 
domains. The ability of purified natural variants of human factor IX to compete with wild-type factor IX binding to the endothelial cell surface was 
used to obtain apparent Ki values of the variants. Our data suggest hat the functional integrity of the Gla domain, enabling factor IX to specifically 
interact with an endothelial cell surface protein, depends on the structural and functional integrity of both the hydrophobic stack domain and the 
first epidermal growth factor-like domain. 
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1. Introduction 
Human factor IX is a 56 kDa glycoprotein that plays 
a key role in the blood coagulation cascade [11. Activated 
factor IX (FIXa) catalyses the conversion of factor X to 
its active form, factor Xa, in a reaction requiring calcium 
ions, phospholipid (a membrane surface) and the cofac- 
tor factor VIIIa. Defective factor IX or a deficiency 
thereof results in the blood clotting disorder haemophilia 
B. The mature form of human factor IX is made up of 
five domains [2]. The amino-terminal domain contains 
12 glutamate residues which are y-carboxylated in a vita- 
min K-dependent reaction giving y-carboxyglutamate 
(Gla), a post-translational modification which is essen- 
tial for activity [3]. The C-terminal end of the Gla do- 
main consists of eight residues which are frequently re- 
ferred to as the hydrophobic stack domain and are coded 
by a separate xon. Both of the domains that follow the 
hydrophobic stack contain the highly conserved arrange- 
ment of 6 cysteine residues characteristic of human epi- 
dermal growth factor. The first of these epidermal 
growth factor-like (EGF-like) domains contains a high- 
affinity calcium-binding site [4]. Furthermore, this do- 
main contains three post-translational modifications. It 
has been demonstrated that Ser-53 and and Ser-61 are 
0-glycosylated [5,6], while 30% of all human factor IX 
molecules are B-hydroxylated at Asp-64 [7]. The second 
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EGF-like domain is followed by the activation peptide 
which contains two N-linked carbohydrates at residues 
Asn-157 and Asn-167. The activation peptide is cleaved 
between residues 145-146 and residues 180-181 either by 
the action of factor VIIa or by factor XIa resulting in the 
active, two-chain form of factor IX, factor IXa. Finally, 
the carboxy-terminal domain of human factor IX con- 
tains the catalytic site and has recently been shown to 
contain a high-affinity calcium-binding site [8]. 
After activation, the four amino-terminal domains 
form the light chain of factor IX which is disulphide- 
bonded to the heavy chain containing the catalytic do- 
main. While the function of the catalytic domain is clear, 
the functions of the light chain domains are less well 
understood. Mutagenesis and domain-exchange xperi- 
ments have implicated both EGF-like domains in the 
interaction between factor IX with both factors VIII and 
X [9, lo]. The Gla domain is known to be required for the 
interaction of factor IX with phospholipid [ 111. The Gla 
residues, which form low-affinity calcium-binding sites 
[12,13], are believed to form an area of high local nega- 
tive charge which could allow non-specific calcium 
bridging with the negatively charged head groups of the 
endothelial membrane surface [14]. 
The Gla domain has also been shown to contain a 
recognition element for the specific binding of factor IX 
to an endothelial cell surface protein [9,15,16]. The pres- 
ence of a human factor IX binding protein on the endo- 
thelial cell surface was initially described by Stern et al. 
[17]. These studies demonstrated that both the zymogen 
and activated forms of human factor IX bound to cul- 
tured endothelial cells with a & of 2.3 nM. The isolated 
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Gla domain from bovine factor IX inhibited the binding 
of full-length factor IX to endothelial cells with a Ki of 
60 nM while a synthetic peptide corresponding to the 
first EGF-like domain of factor IX inhibited the binding 
with a Ki of only 35 ,uM [15]. The role of the Gla domain 
in endothelial cell binding was confirmed by Astermark 
and Stenflo [9], who demonstrated that while a proteolyt- 
ically-derived peptide corresponding to the Gla domain 
linked to both the EGF-like domains inhibited the bind- 
ing of factor IX to endothelial cells, Gla-domainless fac- 
tor IX did not inhibit the binding. More recently, it was 
shown that a chimeric factor IX molecule containing the 
Gla domain of factor VII failed to inhibit factor IX 
binding to endothelial cells, while a chimeric factor VII 
containing the Gla domain from factor IX inhibited 
binding [ 181. Finally, Cheung et al. [ 161 have pin-pointed 
the specific binding region to residues 3-l 1 of human 
factor IX using a combination of chimeric coagulation 
factors and site-directed mutagenesis. 
A specific role of the first EGF-like domain in the 
interaction of factor IX with the endothelial cell surface 
protein has been ruled out [19]. However, an emerging 
feature from studies on coagulation factors is the interde- 
pendence of the domains [20]. To investigate whether the 
Gla domain is dependent on any properties of the adja- 
cent EGF-like domains for endothelial cell binding, we 
have studied the ability of 5 natural variants of factor IX 
to inhibit the binding of wild-type factor IX to endothe- 
lial cells. 
2. Materials and methods 
2.1. Protein purification 
All five factor IX mutants were obtained as 25 ml plasma samples 
from the patients listed in Table 1. Each of the plasma samples was 
assayed for factor IX antigen by ELISA [21] using the antibody 3A6 
[22]. The factor IX variants were purified in a single step by afhnity 
purification on affigel-10 (Bio-Rad) to which either 3A6 or the divalent 
cation-dependent antibody A7 [23] had been covalently coupled (ac- 
cording to the manufacturer’s instructions). Each plasma sample was 
buffer exchanged into 1 x TBS (150 mM NaCl, 20 mM Tris-HCl pH 
7.2), run onto a 0.5 ml affinity column which was subsequently washed 
with 1 x TBS. For each A7 column, the 1 x TBS was supplemented with 
20 mM MgCl,. Factor IX bound to the A7 column was eluted with 
1 x TBS containing 20 mM EDTA while factor IX bound to the 3A6 
column was eluted with 3 M NaSCN. The factor IX samples were then 
dialysed against 1 x TBS and concentrated in a centricon- micro- 
concentrator (Amicon). The clotting activities of the purified factor IX 
mutants were assayed in a one stage clotting assay [24]. Wild-type factor 
IX was labelled with “‘1 using the enzymobead reagent (Bio-Rad) 
according to the manufacturer’s instructions. 
2.2. Western blot analysis 
After 12% polyacrylamide gel electrophoresis [25] proteins were 
transferred onto nitrocellulose by electroblotting in 25 mM Tris, 150 
mM glycine, 20% methanol at 100 V for 1 h. The filters were blocked 
in 12 TBS (150 mM NaCl, 20 mM Tris-HCl pH 7.2) containing 0.1% 
Triton X-100 and 5% low fat milk uowder and incubated for 1 h with 
either the monoclonal antibody 3A6 or A7. The filters were washed 
with 1 x TBS and incubated for one hour with a 1 in 1000 dilution of 
anti-mouse IgG conjugated to horse radish peroxidase (Sigma) in 
1 x TBS/O.I% v Triton X-10015% milk powder. All solutions were sup- 
plemented with 5 mM CaCl, if the antibody A7 was used. The filters 
were developed using the ECL detection reagent (Amersham). 
2.3. Endothelial cell culture 
Human umbilical vein endothelial cells were isolated by standard 
methods [26,27]. The cells were cultured on gelatin-coated tissue culture 
flasks in Ml99 (Gibco-BRL) supplemented with 20% heat-inactivated 
foetal calf serum. The cells were subcultured by trypsin treatment. All 
experiments were performed on passage 3 cells. 
2.4. Endothelial cell binding assay 
Endothelial cells were grown in 6 mm wells until they were 1 day 
pre-confluent. The medium was then replaced with serum-free medium 
containing 4% Ultroser G (G&co-BRL) and the cells incubated for 
another 24 h. The cells were washed once with binding buffer (137 mM 
NaCl, 4 mM KCl, 5.5 mM glucose, 5 mg/ml bovine serum albumin, 2.5 
mM CaCl, and 10 mM HEPES, pH 7.45) and incubated with 50 ~1 of 
binding buffer containing 3.5 nM [‘251]factor IX and increasing 
amounts of the competing factor IX variants. After 60 min incubation 
at room temperature, the cells were washed extensively with binding 
buffer and then solubilised by incubation in 50 ~1 solubilisation buffe; 
(0.2 M NaOH, 1% SDS, 10 mM EDTA). The cell extracts were counted 
in an LKB 1261 Multigamma counter. 
3. Results and discussion 
The natural variants of factor IX were all selected 
from the haemophilia B database [28] according to a 
number of criteria. Since only 25 ml of plasma was avail- 
able, we selected patients with near normal factor IX 
antigen levels (100% or 5 &ml), so that sufficient factor 
IX could be purified for our studies. Also, the ease of 
obtaining the plasma samples and the patients’ HIV 
status had to be taken into account. Table 1 shows the 
5 mutants selected. All, except Lys-43+Glu, were puri- 
Table 1 
Characteristics of the factor IX variants 
Factor IX 
variants 
Factor IX Specific Specific Patient 
antigen” clotting clotting identification 
activity of activity of numbef 
plasmab purified 
factor IXd 
Wild-type 100 100 100 _ 
Phe-9+Ile 100 14 90 51 
Lys-43+Glu 90 15.5 150 83 
Asp-47+Glu 84 1.2 or 10 90 
16.7’ 
Asp-64dAsn 110 2.7 10 114 
Val-107+Ala 114 17.5 20 133 
‘Determined by 3A6 ELISA (see section 2), and expressed as a percent- 
age of the antigen found in a pool of normal human plasma (5 &ml). 
11 values compare well with the published figures [28]. 
bathe percent clotting activities [28] were recalculated as specific clotting 
activities, defined as percent clotting activity divided by percent antigen 
(results column 2). Results are expressed as a percentage. 
Two different figures have been calculated [28] the first from patient 
number 90 (used here) and the second from patient number 89 with an 
identical mutation. An independent assay of the plasma of patient 90 
(see section 2) gave a figure of 8.3%. 
dThe specific clotting activities of the purified factor IX variants ex- 
pressed as a percentage of normal factor IX (100%). 
‘According to [28]. 
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fied using an affinity column of coupled monoclonal 
antibody A7 which recognises a divalent metal ion-de- 
pendent epitope (see section 2). Lys-43+Glu does not 
retain the A7 epitope and was, therefore, purified using 
an affinity column of coupled monoclonal antibody 3A6 
(see methods). The specific clotting activities of the puri- 
fied factor IX variants were assayed and compared to the 
specific clotting activities calculated from the haemo- 
philia B database [28] as shown in Table 1. Interestingly, 
both purified Phe-B+Ile and Lys-43-+Glu had clotting 
activities within the normal range despite the much lower 
specific clotting activities of the plasma samples. It is 
possible that the divalent metal ion-dependent antibody, 
A7, used in the purification of Phe-9-+Ile, selected for 
the more active subset of factor IX molecules with higher 
levels of y-carboxylation. However, this apparent selec- 
tion would not diminish any local structural changes that 
the mutation might cause, and therefore this variant re- 
mained of interest. 
Western blot analysis (Fig. 1) of the five purified factor 
IX variants demonstrated that each of the mutants, ex- 
cept Lys-43-+Glu, was predominantly present in its zy- 
mogen form. Lys-43+Glu, however, had been almost 
completely activated during the purification procedure, 
giving heavy chain and light chain products (Fig. 1). This 
activation could account for the observed high specific 
clotting activity (150%) since the lag phase of the one 
stage clotting assay [24] would be dramatically reduced. 
Wild-type factor IX purified on a 3A6 column was also 
partly activated suggesting that the method of purifica- 
tion may cause part activation. Since both factor IX and 
its activated form, factor IXa, have the same affinity for 
the endothelial cell surface binding protein [17], this Lys- 
43+Glu variant remained of interest. 
The ability of the five factor IX variants to inhibit the 
binding of iodinated wild-type factor IX to endothelial 
cells was assayed as before [29]. All binding assays were 
carried out on confluent monolayers of passage 3 endo- 
thelial cells in 6 mm wells (see section 2). The apparent 
affinity of the endothelial cells for factor IX was deter- 
mined by performing a simple saturation binding exper- 
iment in which half maximal binding occurred at 15 nM 
factor IX (not shown). A wild-type factor IX control 
competition experiment was carried out in parallel with 
each factor IX variant tested. The data were analysed by 
plotting the fractional inhibition of [‘251]factor IX bind- 
ing to endothelial cells against he concentration of com- 
petitor added. Apparent Ki values were obtained by fit- 
ting the data iteratively to 
6 = [CompetitorI,,,, 
K, + [Inhibitor],,,, 
where 6 = fractional inhibition. Fig. 2 illustrates such 
curves derived for the mutants Phe-9+Ile and Val- 
107+Ala. The apparent Ki values obtained are listed in 
Table 2. All of the variants except Val-107+Ala, which 
- 32.5 
- 27.5 
i 
Fig. 1. Western blot of the purified factor IX variants. Two wild-type 
factor IX controls are included. The wild-type factor IX in the far left 
lane was purified on a 3A6 affinity column, while that in the far right 
lane was purified on an A7 affinity column (see section Z).The positions 
of control molecular weight protein standards are indicated. Due to the 
presence of N- and O-linked carbohydrate, intact factor IX has an 
apparent molecular weight of - 75 kDa, the light chain - 30 kDa, the 
heavy chain - 34 kDa. 
is a mutation within the second EGF-like domain, are 
impaired in their ability to compete with wild-type factor 
IX for endothelial cell surface binding. Val-107-+Ala 
competed as well as wild-type factor IX for endothelial 
cell surface binding (Fig. 2b). This result is important in 
two respects. Firstly, it acts as a positive control for the 
binding of the plasma-purified mutants to the endothe- 
lial cell surface, and secondly it suggests that amino acid 
107 of the second EGF-like domain is unlikely to be 
involved directly in the binding of factor IX to the endo- 
thelial cell surface. 
The factor IX variant Lys-43+Glu had the highest 
apparent K, (Table 2) suggesting that the structural integ- 
rity of the hydrophobic stack domain of factor IX is 
important in maintaining the recognition element for 
endothelial cell binding. While it is possible that this 
residue is involved directly in an interaction with endo- 
thelial cells, this is improbable in light of the data from 
Astermark et al. [30], who show that a peptide compris- 
ing residues l-37 of bovine factor IX competes efficiently 
(K,w180 nM) with intact bovine factor IX for endothelial 
cell surface binding. The variants Phe-9+Ile, Asp- 
47+Glu and Asp-64+Asn also have increased apparent 
Ki values. Although these increased values cannot be 
interpreted as identifying the residues directly involved 
in the binding to endothelial cells, they do suggest hat 
changes in local structure or chemical character at these 
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Fig. 2. Inhibition of human [“‘I]Factor IX binding to endothelial cells 
by the human factor IX variants (A) Phe-9+Ile and (B) Val-107+Ala. 
o = wild-type human factor IX, + = variant factor IX. The curves were 
fitted as described in the text. Each experiment was performed once in 
triplicate and the mean of the values obtained plotted. 
positions indirectly effect this binding. Residues Asp-47 
and Asp-64 of the first EGF-like domain have both been 
identified as direct ligands in a calcium ion binding site 
[31]. The changes Asp-47+Glu and Aspd4+Asn are 
known to reduce and abolish calcium binding, respec- 
tively, [31]. Although the first EGF-like domain is not 
known to contain any elements that confer specificity of 
binding to the endothelial cell surface binding protein 
[16], our data suggest that the structural integrity or 
stability of this domain, conferred by calcium-binding, 
is important for optimal binding of factor IX to the 
endothelium. 
It has recently been demonstrated by two different 
approaches that the Gla domain interacts with the first 
EGF-like domain. Firstly, studies of calcium-binding to 
the Gla domains of bovine factors IX and X have shown 
that the isolated domains bind calcium less well than the 
intact proteins. However, when the Gla domains are 
linked to their respective EGF-like domains, the aflinity 
of the calcium-binding sites are similar to those of the 
intact proteins [30,32]. Thus, the first EGF-like domain 
cooperates with the Gla domain in forming the optimal 
structure for calcium binding. Secondly, thermodynamic 
analysis of the temperature-induced melting of factor IX 
has demonstrated that there is a strong interaction be- 
tween the Gla and first EGF-like domains, but that the 
interaction between the two EGF-like domains is much 
weaker [20]. 
Thus the reduced ability of the natural factor IX vari- 
ants studied here to compete with wild-type factor IX for 
the binding to the endothelial cell surface suggests that 
these mutations indirectly affect the recognition element 
within factor IX by disrupting the stability of the Gla- 
first EGF-like domain interaction. Since the specific 
binding of human factor IX to endothelial cells is re- 
ported to be mediated by residues 3-l 1 of the Gla do- 
main [16], the mutation Phe-9+Ile may affect the bind- 
ing site directly, while the mutations Lys-43+Glu, Asp- 
47+Glu and Asp-64+Asn may affect the interaction 
between factor IX and the endothelial cell surface bind- 
ing protein by destabilising the interaction between the 
Gla domain and the first EGF-like domain, as discussed 
above. The study by Vysotchin et al. [20] demonstrated 
that the second EGF-like domain only interacts weakly 
with the first EGF-like domain and therefore, it is un- 
likely that small structural alterations in the second 
EGF-like domain will have an effect on the endothelial 
cell binding determinant of factor IX. This is indeed what 
we have observed with variant Val-107+Ala. Further- 
more, it should be noted that this variant retains only 
20% of normal clotting activity implying that the muta- 
tion is not simply silent but has a detrimental effect on 
a different aspect of factor IX function. 
In summary, our results are consistent with previously 
published data describing the identification of the bind- 
Table 2 
Apparent & values for the inhibition of [“‘I]factor IX binding to the 
endothelial cell surface 
Competitor Apparent K, @M) 
Wild-type factor IX 0.40.6 
Phe-9+Ile 2.4 
Lys-43+Glu 7.4 
Asp_47+Glu 3.5 
Asp&t+Asn 2.9 
Val- 107+Ala 0.66 
78 
ing determinants on factor IX for the endothelial cell 
surface ([ 15,16,18,19]. Our results suggest hat a precise 
interaction between the first EGF-like domain and the 
Gla domain is required for optimal binding. Further- 
more, we have demonstrated a mutation in the second 
EGF-like domain, while clearly being detrimental to fac- 
tor IX activity, has no effect on the interaction of factor 
IX with the endothelial cell surface. This is consistent 
with Vysotchin et al. [20], suggesting a minimal func- 
tional interaction between the second EGF-like domain 
and those domains N-terminal to it. Thus, we conclude 
that while a single domain may contain the element hat 
confers specificity of binding, the optimal conformation 
required by the binding element may depend on an inter- 
action with a number of adjacent domains. 
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